RxDoctor Payments Data

Karla Witzke, DO

Urology · Midland, MINPI 1922202258

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $13,200 of the $18,381 with a category attached, or 71.8%. Olympus America Inc. accounts for 75.2% of it on its own, with 18 other manufacturers making up the rest.

$18,381in general payments, 2019–2025

Across 174 payments — averaging $105.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Olympus America Inc.$14K
  • Medtronic$1K
  • Axonics, Inc.$935
  • Boston Scientific$363
  • Teleflex LLC$334
  • Coloplast$298
  • plus $1K from 13 others

What the payments were for

  • Speaking & faculty fees$13,20072%
  • Food & beverage$5,05628%
  • Education$1251%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,381 in reported general payments places this provider in the 85th percentile of 400 urology providers in Michigan.

See all urology providers in Michigan

Medicare billing

Part B allowed, 2024
$127,874
Medicare patients
462
Services billed
1,242

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron204$170,840
ElmironPentosan Polysulfate Sodium33$36,981
Mirabegron ErMirabegron53$33,743
Tamsulosin Hcl1,247$24,860
GemtesaVibegron15$18,746
Trospium Chloride283$14,410
Trospium Chloride ErTrospium Chloride63$13,437
Finasteride639$11,582
Estradiol191$11,454
Potassium Citrate ErPotassium Citrate73$6,127
Silodosin54$4,639
Alfuzosin Hcl ErAlfuzosin Hcl133$3,130
Solifenacin Succinate52$3,045
Bethanechol Chloride32$1,819
Oxybutynin Chloride ErOxybutynin Chloride53$1,601

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$43$170,840204 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 400 urology providers in Michigan.

Other urology in Midland

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →